---

---

publishing date : 2022 - 11 - 10    tags : Cancer   

save search

---

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-10 (Crawled : 23:00) - globenewswire.com
CRSP M | $55.04 -1.99% -2.03% 1.8M |

Health Technology

| 0.66% | O: -1.01% H: 14.93% C: 11.47%
crispr immunotherapy meeting therapeutics cancer

---

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Published: 2022-11-10 (Crawled : 21:00) - globenewswire.com
GTBP | $3.8001 1.3% 5.9K |

Manufacturing

| 76.56% | O: 0.24% H: 4.53% C: 1.67%
biopharma immunotherapy meeting cancer

---

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
Published: 2022-11-10 (Crawled : 18:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M |

Health Technology

| 13.25% | O: 5.25% H: 9.9% C: 8.71%
nx-1607 immunotherapy meeting cancer

---

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
Published: 2022-11-10 (Crawled : 18:00) - biospace.com/
BCTX | $2.19 -5.6% -5.94% 140K |

Professional, Scientific, and T...

| -50.45% | O: 5.92% H: 2.71% C: -0.51%
treatment immunotherapy meeting breast positive cancer

---

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 18:00) - globenewswire.com
IOVA | News M | $11.32 -3.41% -3.53% 5.3M |

Health Technology

| 44.26% | O: 6.12% H: 4.99% C: 4.21%
melanoma immunotherapy meeting cancer

---

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-10 (Crawled : 17:00) - biospace.com/
HOWL | $5.91 0.68% 0.68% 120K |

Professional, Scientific, and T...

| 165.77% | O: 6.08% H: 0.21% C: -2.76%
wtx-330 preclinical immunotherapy meeting therapeutics il-12 cancer

---

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 16:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M |

Health Technology

| -65.36% | O: 2.23% H: 7.24% C: 6.28%
nktr-288 preclinical immunotherapy meeting therapeutics cancer

---

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Published: 2022-11-10 (Crawled : 15:20) - biospace.com/
CDAK | $0.057 -55.99% -131.25% 0 |

Health Technology

| -92.5% | O: 2.04% H: 9.65% C: 5.78%
preclinical immunotherapy meeting cancer

---

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 15:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 65.8% | O: -1.69% H: 0.1% C: -3.37%
research immunotherapy meeting therapy cancer

---

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-10 (Crawled : 14:20) - biospace.com/
SQZ | $0.435 0.0% 30M |

Health Technology

| -82.87% | O: 9.84% H: 1.43% C: -3.23%
ander-001 squeeze preclinical sqz immunotherapy meeting mrna trial cancer

---

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Published: 2022-11-10 (Crawled : 14:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K |

Health Technology

| -38.2% | O: 5.06% H: 6.42% C: 4.81%
biotech meeting response cancer pancreatic

---

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:20) - allogene.com
ALLO | $3.48 0.58% 0.57% 2M |

Health Technology

| -60.39% | O: 4.79% H: 5.66% C: 3.92%
immunotherapy meeting control therapeutics cancer

---

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
SCPS | $0.1682 |

| 41.77% | O: 3.29% H: 12.99% C: 10.73%
immunotherapy meeting cancer

---

Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 14:00) - investors.senseibio.com
SNSE | $1.03 4.79% 4.57% 24K |

| -29.2% | O: 2.92% H: 7.09% C: 6.38%
preclinical immunotherapy meeting cancer

---

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K |

Health Technology

| 748.46% | O: 3.0% H: 6.78% C: 1.69%
trials immunotherapy meeting pepinemab cancer

---

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
Published: 2022-11-10 (Crawled : 14:00) - investors.phiopharma.com
PHIO | $0.631 -1.07% -1.08% 29K |

Health Technology

| -90.83% | O: 6.63% H: 3.0% C: -12.9%
pharmaceuticals immunotherapy meeting cancer study

---

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
Published: 2022-11-10 (Crawled : 13:20) - globenewswire.com
PVCT 4 | $0.195 -15.0% 56K |

Manufacturing

| 249.26% | O: -2.57% H: 3.77% C: 1.89%
pv-10 melanoma immunotherapy cancer

---

NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 09:00) - biospace.com/
NBTX | $5.69 3.45% 3.34% 1.6K |

Manufacturing

| Email alert Add to watchlist
immunotherapy meeting potential cancer

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---